Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme.
Conclusion: The safety profile of cabazitaxel in this pooled analysis of two cabazitaxel early access programmes was manageable and consistent with previous Phase III trials (TROPIC, PROSELICA).
PMID: 31289614 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Chemotherapy | Diarrhoea | Docetaxel | Oral Cancer | Prednisolone | Prednisone | Prostate Cancer | Taxotere